AtomVie Global Radiopharma, a global radiopharmaceutical contract development and manufacturing organization (CDMO), has entered a strategic partnership with Jubilant Radiopharma. Under a Logistics and Regulatory Services Agreement, Jubilant Radiopharma will provide logistics, regulatory, and last-mile distribution services to support AtomVie’s expanding portfolio of radiopharmaceutical programs. The collaboration is intended to strengthen radiopharmaceutical logistics as AtomVie’s programs grow.
Jubilant Radiopharma will handle the receipt and handling of AtomVie-manufactured radiopharmaceuticals, support regulatory compliance, and manage last-mile distribution through its U.S. pharmacy network. The arrangement is designed to streamline deliveries to clinical sites while upholding the quality, safety, and regulatory compliance standards required for radiopharmaceutical products.
Bruno Paquin, Chief Executive Officer of AtomVie, said, “As the radiopharmaceutical sector continues to grow, establishing strong logistics and distribution capabilities is essential to ensuring patients and clinical sites receive products reliably and efficiently.”
“We are pleased to partner with Jubilant Radiopharma, whose extensive pharmacy network, regulatory expertise, and commitment to quality make them an ideal collaborator as we expand support for our customers’ clinical development programs, build the infrastructure needed to advance future clinical radiopharmaceutical therapies, and further our goal of transforming patients’ lives with high quality radiopharmaceuticals,” he added.
Shared Focus on Safe and Reliable Delivery
Harsher Singh, Chief Executive Officer, Jubilant Radiopharma, said, “Jubilant Radiopharma is committed to advancing the safe, compliant, and reliable delivery of radiopharmaceutical therapies across North America.”
“As a trusted partner for therapeutic clinical trials and commercialization, we provide the specialized infrastructure, regulatory expertise, therapeutic dispensing capabilities, and national delivery network required to support radiopharmaceuticals throughout their lifecycle. Our collaboration with AtomVie reflects a shared commitment to accelerating innovation and expanding patient access to the next generation of radiopharmaceutical therapies,” he added.
The partnership further strengthens AtomVie’s integrated service offering. By drawing on Jubilant Radiopharma’s established distribution infrastructure and capabilities in clinical trials, therapeutic dispensing, and commercialization, AtomVie and its clients are expected to gain improved access to clinical trial sites and greater operational flexibility as development programs progress. The agreement brings logistics, regulatory support, and distribution together to support radiopharmaceutical logistics across the clinical development process.
